MedTrace Logo

A Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes

NCT05514080 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-08-24

No results posted yet for this study

Summary

The objective of this study is to generate preliminary data in an inpatient setting to help optimize an insulin dosing logic (that decides how much to deliver insulin) for Eli Lilly's system.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

OTHER

Insulin closed-loop

41-hour intervention period in which the participants are treated with rapid insulin in the closed-loop system.

Sponsors & Collaborators

Principal Investigators

  • Michael Tsoukas, MD · Royal Victoria Hospital, Belfast

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-06
Primary Completion
2021-09-04
Completion
2022-03-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05514080 on ClinicalTrials.gov